Pluri (PLUR) Competitors $4.99 +0.09 (+1.73%) Closing price 03:57 PM EasternExtended Trading$4.81 -0.17 (-3.43%) As of 05:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PLUR vs. CYBN, LFVN, CTOR, NKTX, MIST, CRDF, ONCY, ZURA, IVVD, and GNLXShould you be buying Pluri stock or one of its competitors? The main competitors of Pluri include Cybin (CYBN), Lifevantage (LFVN), Citius Oncology (CTOR), Nkarta (NKTX), Milestone Pharmaceuticals (MIST), Cardiff Oncology (CRDF), Oncolytics Biotech (ONCY), Zura Bio (ZURA), Invivyd (IVVD), and Genelux (GNLX). These companies are all part of the "pharmaceutical products" industry. Pluri vs. Its Competitors Cybin Lifevantage Citius Oncology Nkarta Milestone Pharmaceuticals Cardiff Oncology Oncolytics Biotech Zura Bio Invivyd Genelux Cybin (NYSE:CYBN) and Pluri (NASDAQ:PLUR) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, media sentiment, valuation, earnings, institutional ownership, analyst recommendations and dividends. Do analysts prefer CYBN or PLUR? Cybin currently has a consensus price target of $85.00, indicating a potential upside of 1,307.28%. Pluri has a consensus price target of $12.00, indicating a potential upside of 140.72%. Given Cybin's stronger consensus rating and higher possible upside, equities research analysts plainly believe Cybin is more favorable than Pluri.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cybin 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Pluri 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk & volatility, CYBN or PLUR? Cybin has a beta of 0.68, meaning that its stock price is 32% less volatile than the S&P 500. Comparatively, Pluri has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500. Which has higher earnings & valuation, CYBN or PLUR? Pluri has higher revenue and earnings than Cybin. Cybin is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCybinN/AN/A-$57.88M-$4.60-1.31Pluri$330K118.88-$20.89M-$5.53-0.90 Is CYBN or PLUR more profitable? Cybin has a net margin of 0.00% compared to Pluri's net margin of -2,563.29%. Cybin's return on equity of -37.58% beat Pluri's return on equity.Company Net Margins Return on Equity Return on Assets CybinN/A -37.58% -36.59% Pluri -2,563.29%-4,191.91%-85.40% Do institutionals and insiders believe in CYBN or PLUR? 17.9% of Cybin shares are held by institutional investors. Comparatively, 16.6% of Pluri shares are held by institutional investors. 15.0% of Cybin shares are held by insiders. Comparatively, 25.9% of Pluri shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the media refer more to CYBN or PLUR? In the previous week, Cybin and Cybin both had 5 articles in the media. Pluri's average media sentiment score of 0.58 beat Cybin's score of 0.00 indicating that Pluri is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cybin 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pluri 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryCybin beats Pluri on 9 of the 15 factors compared between the two stocks. Get Pluri News Delivered to You Automatically Sign up to receive the latest news and ratings for PLUR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PLUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PLUR vs. The Competition Export to ExcelMetricPluriMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$39.23M$3.08B$5.69B$10.27BDividend YieldN/A2.32%5.72%4.60%P/E Ratio-0.9021.3075.8626.51Price / Sales118.88379.80489.92165.32Price / CashN/A44.4425.8129.89Price / Book4.999.6112.846.32Net Income-$20.89M-$53.28M$3.28B$270.51M7 Day Performance5.61%0.31%0.22%2.15%1 Month Performance0.30%4.58%4.61%6.35%1 Year Performance-5.05%9.24%68.33%25.48% Pluri Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PLURPluri2.7103 of 5 stars$4.99+1.7%$12.00+140.7%-13.6%$39.23M$330K-0.90150Upcoming EarningsCYBNCybin2.1418 of 5 stars$6.30+0.5%$85.00+1,249.2%N/A$148.64MN/A-1.4450LFVNLifevantage3.9973 of 5 stars$11.58+1.2%$30.50+163.4%+1.7%$147.72M$228.53M15.73260CTORCitius Oncology1.7899 of 5 stars$1.87+1.4%$3.00+60.9%+12.9%$146.79MN/A0.00N/AGap UpNKTXNkarta2.3583 of 5 stars$2.08-2.1%$13.60+555.4%-65.5%$146.68MN/A-1.40140Positive NewsGap UpMISTMilestone Pharmaceuticals2.4366 of 5 stars$1.72-1.9%$5.00+191.4%+29.6%$146.61M$1M-2.0530CRDFCardiff Oncology2.8632 of 5 stars$2.16-3.4%$10.63+393.0%-24.7%$144.04M$680K-2.4920Positive NewsONCYOncolytics Biotech2.4147 of 5 stars$1.37+6.6%$5.00+266.3%+29.7%$138.00MN/A-5.0930News CoverageGap UpHigh Trading VolumeZURAZura Bio3.5918 of 5 stars$2.14-3.4%$14.00+555.7%-48.1%$137.84MN/A-3.033Short Interest ↓IVVDInvivyd3.4761 of 5 stars$1.16-0.4%$3.18+175.6%+11.3%$137.56M$25.38M-1.24100Short Interest ↑GNLXGenelux1.4625 of 5 stars$3.58+0.6%$20.33+468.0%+60.7%$135.22M$10K-4.1610Positive News Related Companies and Tools Related Companies Cybin Competitors Lifevantage Competitors Citius Oncology Competitors Nkarta Competitors Milestone Pharmaceuticals Competitors Cardiff Oncology Competitors Oncolytics Biotech Competitors Zura Bio Competitors Invivyd Competitors Genelux Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PLUR) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersFanatics Hit $31B-Is This Nasdaq Next?Fanatics built an empire by owning the fan experience-scaling to a $31B valuation. But the next wave isn't abo...i2i Marketing Group, LLC | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredFree: The Crypto Summit That Could Change Your LifeWall Street’s Crypto Playbook—Revealed at This Free Event If you want to understand what's really happening...Crypto 101 Media | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredOpenAI’s new $300 billion dealOpenAI just signed a $300 billion cloud deal with Oracle to secure the computing power needed for its next Cha...Porter & Company | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pluri Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pluri With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PLUR Stock Alerts